19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt

Hansoh Pharma announced information related to olatorepatid (HS-20094), its internally developed dual agonist, in connection with the European Association for the Study of Diabetes (EASD) annual meeting in Milan from September 28 to October 2, 2026. The provided article text does not disclose clinical efficacy, safety, regulatory, or financial results.